Single-Domain Albumin Binding Protein for Extended Therapeutic Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic molecules have short circulatory half-lives, necessitating improved methods to extend their duration in the bloodstream for effective therapeutic delivery.
Innovation Solution
Development of a single domain serum albumin binding protein with specific complementarity determining regions (CDRs) that bind to serum albumin, enhancing the half-life of therapeutic molecules by associating non-covalently with albumin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If therapeutic molecules are administered, then therapeutic effect is achieved, but circulatory half-life is short requiring frequent dosing
Solution Approach 1:
The patent introduces a single domain albumin binding protein as an intermediary that non-covalently associates with therapeutic molecules. This intermediary binds to serum albumin with high affinity, effectively using albumin as a carrier to extend the circulatory half-life of the therapeutic molecule without requiring covalent modification
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of therapeutic molecules by changing their binding characteristics. The single domain protein alters the molecular weight, binding affinity, and serum residence time parameters of the therapeutic molecule through non-covalent association, thereby extending half-life from hours to days
2Reliability
If therapeutic molecules are administered, then therapeutic effect is achieved, but pharmacokinetics and tissue distribution need improvement
Solution Approach 1:
The single domain albumin binding protein serves multiple functions simultaneously: it extends circulatory half-life, improves pharmacokinetic profile, and enhances tissue distribution particularly to tumor sites. By binding to albumin, it leverages albumin's natural ability to distribute throughout the body and accumulate in tissues with increased vascular permeability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The single domain serum albumin binding protein extends the elimination half-time of therapeutic molecules by 12 to 100 hours, improving pharmacokinetics and tissue distribution, particularly in tumors.
Implementation Method 1
enhancing the half-life of therapeutic molecules by associating non-covalently with albumin
Data Source
AI summary
Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.